In hepatocellular carcinoma resistant against the tyrosine kinase inhibitor sorafenib, a higher glutamine metabolism and reductive glutamine carboxylation dependent on PPARβ/δ were reported. The gene discussed is PPARD; the disease is hepatocellular carcinoma.